Novel therapeutic targets of metformin: metabolic syndrome and cardiovascular disease

Bibliography

• American Diabetes Association. Standards of medical care in diabetes–2014. Diabetes Care 2014;37(Suppl 1):S14-80
   PubMed Web of Science ®Google Scholar
• Rena G, Pearson ER, Sakamoto K. Molecular mechanism of action of metformin: old or new insights? Diabetologia 2013;56:1898-906
   PubMed Web of Science ®Google Scholar
• Grundy SM. Pre-diabetes, metabolic syndrome, and cardiovascular risk. J Am Coll Cardiol 2012;59:635-43
   PubMed Web of Science ®Google Scholar
• Fuster V. Global burden of cardiovascular disease: time to implement feasible strategies and to monitor results. J Am Coll Cardiol 2014;64:520-2
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-52
   PubMed Web of Science ®Google Scholar
• El Messaoudi S, Rongen GA, Riksen NP. Metformin therapy in diabetes: the role of cardioprotection. Curr Atheroscler Rep 2013;15:314
   PubMed Web of Science ®Google Scholar
• Wong AK, Struthers AD, Choy AM, et al. Insulin sensitization therapy and the heart: focus on metformin and thiazolidinediones. Heart Fail Clin 2012;8:539-50
   PubMed Web of Science ®Google Scholar
• Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 2000;348 Pt 3:607-14
   PubMed Web of Science ®Google Scholar
• Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol 2012;13:251-62
   PubMed Web of Science ®Google Scholar
• Hawley SA, Ross FA, Chevtzoff C, et al. Use of cells expressing gamma subunit variants to identify diverse mechanisms of AMPK activation. Cell Metab 2010;11:554-65
   PubMed Web of Science ®Google Scholar
• Foretz M, Hebrard S, Leclerc J, et al. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest 2010;120:2355-69
   PubMed Web of Science ®Google Scholar
• Miller RA, Chu Q, Xie J, et al. Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature 2013;494:256-60
   PubMed Web of Science ®Google Scholar
• Davis BJ, Xie Z, Viollet B, et al. Activation of the AMP-activated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase. Diabetes 2006;55:496-505
   PubMed Web of Science ®Google Scholar
• Ouslimani N, Peynet J, Bonnefont-Rousselot D, et al. Metformin decreases intracellular production of reactive oxygen species in aortic endothelial cells. Metabolism 2005;54:829-34
   PubMed Web of Science ®Google Scholar
• Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365:1415-28
   PubMed Web of Science ®Google Scholar
• Salpeter SR, Buckley NS, Kahn JA, et al. Meta-analysis: metformin treatment in persons at risk for diabetes mellitus. Am J Med 2008;121:149-57. e2
   PubMed Web of Science ®Google Scholar
• Jellis C, Martin J, Narula J, et al. Assessment of nonischemic myocardial fibrosis. J Am Coll Cardiol 2010;56:89-97
   PubMedGoogle Scholar
• Kosmala W, Przewlocka-Kosmala M, Wojnalowicz A, et al. Integrated backscatter as a fibrosis marker in the metabolic syndrome: association with biochemical evidence of fibrosis and left ventricular dysfunction. Eur Heart J Cardiovasc Imaging 2012;13:459-67
   PubMed Web of Science ®Google Scholar
• Boudina S, Abel ED. Diabetic cardiomyopathy revisited. Circulation 2007;115:3213-23
   PubMed Web of Science ®Google Scholar
• Stratmann B, Tschoepe D. Heart in diabetes: not only a macrovascular disease. Diabetes Care 2011;34(Suppl 2):S138-44
   PubMedGoogle Scholar
• Mizushige K, Yao L, Noma T, et al. Alteration in left ventricular diastolic filling and accumulation of myocardial collagen at insulin-resistant prediabetic stage of a type II diabetic rat model. Circulation 2000;101:899-907
   PubMed Web of Science ®Google Scholar
• McGavock JM, Lingvay I, Zib I, et al. Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopy study. Circulation 2007;116:1170-5
   PubMed Web of Science ®Google Scholar
• Eguchi K, Boden-Albala B, Jin Z, et al. Association between diabetes mellitus and left ventricular hypertrophy in a multiethnic population. Am J Cardiol 2008;101:1787-91
   PubMed Web of Science ®Google Scholar
• Nakai H, Takeuchi M, Nishikage T, et al. Subclinical left ventricular dysfunction in asymptomatic diabetic patients assessed by two-dimensional speckle tracking echocardiography: correlation with diabetic duration. Euro J Echocardiogr 2009;10:926-32
   PubMed Web of Science ®Google Scholar
• Zabalgoitia M, Ismaeil MF, Anderson L, et al. Prevalence of diastolic dysfunction in normotensive, asymptomatic patients with well-controlled type 2 diabetes mellitus. Am J Cardiol 2001;87:320-3
   PubMed Web of Science ®Google Scholar
• Burlá AK, Lobato NS, Fortes ZB, et al. Cardiac fibrosis and vascular remodeling are attenuated by metformin in obese rats. Int J Cardiol 2011;165(3):483-7
   PubMedGoogle Scholar
• Cittadini A, Napoli R, Monti MG, et al. Metformin prevents the development of chronic heart failure in the SHHF rat model. Diabetes 2012;61:944-53
   PubMed Web of Science ®Google Scholar
• Xiao H, Ma X, Feng W, et al. Metformin attenuates cardiac fibrosis by inhibiting the TGFbeta1-Smad3 signalling pathway. Cardiovasc Res 2010;87:504-13
   PubMed Web of Science ®Google Scholar
• Zhang CX, Pan SN, Meng RS, et al. Metformin attenuates ventricular hypertrophy by activating the AMP-activated protein kinase-endothelial nitric oxide synthase pathway in rats. Clin Exp Pharmacol Physiol 2011;38:55-62
   PubMedGoogle Scholar
• Fontes-Carvalho R, Ladeiras-Lopes R, Bettencourt P, et al. Diastolic dysfunction in the diabetic continuum : association with insulin resistance, metabolic syndrome and type 2 diabetes. Cardiovasc Diabetol 2015;14:4
   PubMedGoogle Scholar
• Ladeiras-Lopes R, Fontes-Carvalho R, Bettencourt N, et al. METformin in DIastolic Dysfunction of MEtabolic syndrome (MET-DIME) trial: rationale and study design : MET-DIME trial. Cardiovasc Drugs Ther 2014;28:191-6
   PubMedGoogle Scholar
• Ng M, Fleming T, Robinson M, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014;384:766-81
   PubMed Web of Science ®Google Scholar
• Russo C, Jin Z, Homma S, et al. Effect of obesity and overweight on left ventricular diastolic function: a community-based study in an elderly cohort. J Am Coll Cardiol 2011;57:1368-74
   PubMed Web of Science ®Google Scholar
• Lavie CJ, Alpert MA, Arena R, et al. Impact of obesity and the obesity paradox on prevalence and prognosis in heart failure. JACC Heart Fail 2013;1:93-102
   PubMed Web of Science ®Google Scholar
• Powell BD, Redfield MM, Bybee KA, et al. Association of obesity with left ventricular remodeling and diastolic dysfunction in patients without coronary artery disease. J Am Coll Cardiol 2006;98:116-20
   Google Scholar
• Patel SB, Reams GP, Spear RM, et al. Leptin: linking obesity, the metabolic syndrome, and cardiovascular disease. Curr Hypertens Rep 2008;10:131-7
   PubMed Web of Science ®Google Scholar
• Taube A, Schlich R, Sell H, et al. Inflammation and metabolic dysfunction: links to cardiovascular diseases. Am J Physiol Heart Circ Physiol 2012;302:H2148-65
   PubMed Web of Science ®Google Scholar
• Kwon H, Pessin JE. Adipokines mediate inflammation and insulin resistance. Front Endocrinol 2013;4:71
   PubMedGoogle Scholar
• Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 1996;271:10697-703
   PubMed Web of Science ®Google Scholar
• Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999;257:79-83
   PubMed Web of Science ®Google Scholar
• Trujillo ME, Scherer PE. Adiponectin – journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Int Med 2005;257:167-75
   PubMed Web of Science ®Google Scholar
• Heiker JT, Kosel D, Beck-Sickinger AG. Molecular mechanisms of signal transduction via adiponectin and adiponectin receptors. Biol Chem 2010;391:1005-18
   PubMed Web of Science ®Google Scholar
• Mao X, Kikani CK, Riojas RA, et al. APPL1 binds to adiponectin receptors and mediates adiponectin signalling and function. Nat Cell Biol 2006;8:516-23
   PubMed Web of Science ®Google Scholar
• Schmid PM, Resch M, Steege A, et al. Globular and full-length adiponectin induce NO-dependent vasodilation in resistance arteries of Zucker lean but not Zucker diabetic fatty rats. Am J Hypertens 2011;24:270-7
   PubMedGoogle Scholar
• Schmid PM, Resch M, Schach C, et al. Antidiabetic treatment restores adiponectin serum levels and APPL1 expression, but does not improve adiponectin-induced vasodilation and endothelial dysfunction in Zucker diabetic fatty rats. Cardiovasc Diabetol 2013;12:46
   PubMedGoogle Scholar
• Evia-Viscarra ML, Rodea-Montero ER, Apolinar-Jimenez E, et al. The effects of metformin on inflammatory mediators in obese adolescents with insulin resistance: controlled randomized clinical trial. J Pediatr Endocrinol Metab 2012;25:41-9
   PubMedGoogle Scholar
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:854-65
   PubMed Web of Science ®Google Scholar
• Calvert JW, Gundewar S, Jha S, et al. Acute metformin therapy confers cardioprotection against myocardial infarction via AMPK-eNOS-mediated signaling. Diabetes 2008;57:696-705
   PubMed Web of Science ®Google Scholar
• Gundewar S, Calvert JW, Jha S, et al. Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival in heart failure. Circ Res 2009;104:403-11
   PubMed Web of Science ®Google Scholar
• Lexis CP, Wieringa WG, Hiemstra B, et al. Chronic metformin treatment is associated with reduced myocardial infarct size in diabetic patients with ST-segment elevation myocardial infarction. Cardiovasc Drugs Ther 2014;28:163-71
   PubMedGoogle Scholar
• Bhamra GS, Hausenloy DJ, Davidson SM, et al. Metformin protects the ischemic heart by the Akt-mediated inhibition of mitochondrial permeability transition pore opening. Basic Res Cardiol 2008;103:274-84
   PubMed Web of Science ®Google Scholar
• Hausenloy DJ, Yellon DM. The mitochondrial permeability transition pore: its fundamental role in mediating cell death during ischaemia and reperfusion. J Mol Cell Cardiol 2003;35:339-41
   PubMed Web of Science ®Google Scholar
• Paiva M, Riksen NP, Davidson SM, et al. Metformin prevents myocardial reperfusion injury by activating the adenosine receptor. J Cardiovasc Pharmacol 2009;53:373-8
   PubMed Web of Science ®Google Scholar
• Jonassen AK, Brar BK, Mjos OD, et al. Insulin administered at reoxygenation exerts a cardioprotective effect in myocytes by a possible anti-apoptotic mechanism. J Mol Cell Cardiol 2000;32:757-64
   PubMed Web of Science ®Google Scholar
• Jonassen AK, Sack MN, Mjos OD, et al. Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cell-survival signaling. Circ Res 2001;89:1191-8
   PubMed Web of Science ®Google Scholar
• Gao F, Gao E, Yue TL, et al. Nitric oxide mediates the antiapoptotic effect of insulin in myocardial ischemia-reperfusion: the roles of PI3-kinase, Akt, and endothelial nitric oxide synthase phosphorylation. Circulation 2002;105:1497-502
   PubMed Web of Science ®Google Scholar
• Lexis CP, van der Horst IC, Lipsic E, et al. Effect of metformin on left ventricular function after acute myocardial infarction in patients without diabetes: the GIPS-III randomized clinical trial. JAMA 2014;311:1526-35
   PubMedGoogle Scholar
• Agarwal N, Rice SP, Bolusani H, et al. Metformin reduces arterial stiffness and improves endothelial function in young women with polycystic ovary syndrome: a randomized, placebo-controlled, crossover trial. J Clin Endocrinol Metab 2010;95:722-30
   PubMed Web of Science ®Google Scholar
• McCoy RG, Irving BA, Soop M, et al. Effect of insulin sensitizer therapy on atherothrombotic and inflammatory profiles associated with insulin resistance. Mayo Clin Proc 2012;87:561-70
   PubMedGoogle Scholar
• Gin H, Freyburger G, Boisseau M, et al. Study of the effect of metformin on platelet aggregation in insulin-dependent diabetics. Diabetes Res Clin Pract 1989;6:61-7
   PubMed Web of Science ®Google Scholar
• Nagi DK, Yudkin JS. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups. Diabetes care 1993;16:621-9
   PubMed Web of Science ®Google Scholar
• Bhalla RC, Toth KF, Tan E, et al. Vascular effects of metformin. Possible mechanisms for its antihypertensive action in the spontaneously hypertensive rat. Am J Hypertens 1996;9:570-6
   PubMedGoogle Scholar
• Landin-Wilhelmsen K. Metformin and blood pressure. J Clin Pharm Ther 1992;17:75-9
   PubMed Web of Science ®Google Scholar
• He H, Zhao Z, Chen J, et al. Metformin-based treatment for obesity-related hypertension: a randomized, double-blind, placebo-controlled trial. J Hypertens 2012;30:1430-9
   PubMedGoogle Scholar
• Available from: http://www.servier.com/Powerpoint-image-bank
   Google Scholar